BUND FINANCE › Stocks › BDX
Becton, Dickinson and Company (BDX)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +10.19% above its 50-day average.
- It is +25.61% above its 200-day average (long-term uptrend).
- It sits at 90% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | US$18.9B | US$19.4B | US$20.2B | US$21.8B | US$19.5B |
| Net income | US$1.8B | US$1.5B | US$1.7B | US$1.7B | US$1.1B |
| EPS (diluted) | 5.88 | 4.94 | 5.86 | 5.83 | 4.09 |
| Gross margin | 44.9% | 42.2% | 45.2% | 45.4% | 47.4% |
| Operating margin | 12.1% | 10.9% | 11.9% | 11.8% | 11.6% |
| Net margin | 9.4% | 7.7% | 8.5% | 7.7% | 5.9% |
| Free cash flow | US$1.7B | US$2.1B | US$3.1B | US$2.7B | US$2.7B |
| Total debt | US$17.0B | US$16.8B | US$21.6B | US$19.2B | US$16.3B |
| Cash | US$1.2B | US$1.4B | US$1.9B | US$851.0M | US$725.0M |
Compound annual growth: revenue 0.8% · net income -10.4% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 51.4x | 34.3x | 26.4x |
| EV / EBITDA | 15.5x | 14.7x | 16.3x |
| Operating margin | 11.8% | — | 3.6% |
| Net margin | 5.7% | — | -0.0% |
| Debt / equity | 1.06 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Becton, Dickinson and Company
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and ad…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice